Human Tissue in Aesthetics: Cosmetics Are Blocked at the Ingredient

What is the signal?

At the MFDS audit on 13 October 2026, the management gap around aesthetic human tissue products became the central issue. Lawmaker Kim Yun of the Democratic Party argued that human tissue should be classified, managed and verified as a medical device depending on how far it has been processed and its properties altered — the scope of 'minimal manipulation'. Commissioner Oh Yu-kyoung said a policy study on where that threshold sits is under way, and that the minimal manipulation standard and the safety management system will be revised once the study concludes. Money Today TheBio reported that the ministry is studying the processing criteria that separate human tissue from a medical device, and will consider revising the safety management system based on the result.

Advertising was raised alongside it. Kim noted that some clinic websites display wording such as AATB (American Association of Tissue Banks) accreditation, FDA raw material clearance and Korean MFDS approval, pointing out that AATB accredits tissue banks rather than products, and that neither the FDA nor the MFDS procedure amounts to a safety and efficacy approval. Oh acknowledged the institutional limit that the current Human Tissue Act carries no direct provision governing advertising. According to Pharm News, a legal amendment to restrict aesthetic-purpose advertising was already said to be under review at the audit a year earlier, yet the amendment banning such advertising was still at the Ministry of Health and Welfare review stage as of last month. Lawmaker Park Jie-won called for a full inspection of products already on the market, and the ministry agreed to consider it.

On the cosmetic side the line is already drawn. In the MFDS restricted cosmetic ingredient list published through the Drug Safety Portal, 'human cells and tissues and their culture media' appears under the prohibited classification. Culture media may be used only where they conform to the human cell and tissue culture medium safety standard in Annex 3 of the Regulation on Safety Standards for Cosmetics. Labelling and advertising are blocked separately: the ministry revised its cosmetic labelling and advertising guidance to prohibit wording that could be mistaken for the presence of human-derived stem cells, exosomes or liposomes, and phrases such as 'exosome' and 'exosome cosmetic' were included among the prohibited examples. Only clearly non-human origins, such as plant exosomes or milk exosomes, may be expressed.

A note on how far these facts reach. The audit material above is questioning and answers, not an adopted rule. What the ministry stated goes as far as a study in progress and an intention to revise; no draft, standard or effective date has been published. The audit content was confirmed through news reporting, so wording differs slightly between outlets. The detailed items of Annex 3 were confirmed from reporting at the time the standard was introduced, so the text currently in force has to be checked against the notice itself, and figures recorded differently across outlets — such as the record retention period — are safer left unquoted. This article was verified through searches restricted to each source's official domain in an environment where direct page fetching is blocked.

1. In cosmetics, human cells and tissues are an ingredient you cannot use

This is where briefs most often go wrong. When a material that made headlines in the procedure market prompts the suggestion to build a cosmetic around the same ingredient, the first thing to check is not its efficacy but its legal identity. In the MFDS restricted cosmetic ingredient list, 'human cells and tissues and their culture media' sits under the prohibited classification. Cells and tissues themselves cannot be used as a cosmetic ingredient; only culture media may be used, exceptionally, where a separate standard is met.

That line sits ahead of formulation. If an ingredient is on the prohibited list, the conclusion does not change with the format you choose or how far you lower the level. Making samples first and checking the rules later means the format, packaging and unit cost all get built on top of an ingredient that cannot be used before you come back to it.

The products discussed at the audit are not cosmetics but injectables used in medical settings, so this revision does not directly change cosmetic standards. What it does is mix the same material names and stories on the consumer side, which makes it easy for a brief to assume that something used in procedures may also be used in a cosmetic. Writing down that the assumption is wrong is enough.

• Whether you first checked if the material appears under the prohibited classification of the MFDS restricted ingredient list
• Whether 'it is used in procedures' is being written as grounds for cosmetic use
• Whether ingredient identity is confirmed before sample work begins
• Whether the supplier's proposal states cosmetic eligibility explicitly

2. To use a culture medium, Annex 3 comes before the formula

Human cell and tissue culture media are the exception in this category. What matters is that the exception reads not as 'may be used' but as 'only where the standard is met' — conformity with the human cell and tissue culture medium safety standard in Annex 3 of the Regulation on Safety Standards for Cosmetics.

According to reporting from when the standard was introduced, its main elements are donor eligibility testing, collection and testing of cells and tissues, culture facility and environmental control, and the manufacture, safety assessment and testing of the culture medium. The culture medium manufacturing facility was described as requiring an aseptic area at the level used for injectable manufacture. The ministry's amendment records show that a 2015 revision made it mandatory to test the final culture medium for the absence of any raw material not permitted in cosmetics where such a material was added during manufacture.

Translated into a development schedule, the meaning becomes clear. A brief using this ingredient starts not with formulation but with qualifying the supplier. Whether the supplier actually holds donor eligibility records, collection and culture records and test data, and whether the responsible distributor can receive and retain them, is settled before the formula. A retention obligation comes with it, and because the period is recorded differently across outlets, it has to be checked against the notice itself.

Failing it puts the business at stake rather than the product. THE K BEAUTY SCIENCE reported cases of companies caught breaching the record retention obligation in an MFDS inspection, alongside the sanction ladder: a three-month suspension of sales operations on a first breach, rising to cancellation of registration from a fourth. A single ingredient does not stay a single-product problem.

• Whether the supplier can evidence Annex 3 conformity with documents
• Whether a route is set to receive and retain donor eligibility, collection, culture and test records
• Whether the retention period and the responsible party are written into the contract
• Whether ingredient verification sits on the same schedule line as formulation

3. In labelling and advertising, the word 'exosome' is blocked first

Securing the ingredient lawfully does not settle what you may say. The MFDS revised its cosmetic labelling and advertising guidance to prohibit wording that could be mistaken for the presence of human-derived stem cells, exosomes or liposomes. Reporting indicates that phrases such as 'exosome' and 'exosome cosmetic' were given as prohibited examples.

The way through is to make the origin explicit. Expressions are reported to be available where the origin is clearly not human, as with plant exosomes or milk exosomes. So when writing pack copy in this category, it is faster to settle in one line what the material actually comes from than to ask whether the word may be used. Once the origin is fixed, the range of expressions available is fixed with it.

The items blocked in the same revision are worth remembering. Expert designation or recommendation wording such as 'for hospital use', 'hospital exclusive', 'dermatology exclusive', 'pharmacy use' and 'pharmacy exclusive', usage wording that misleads on method such as microneedle, and claims that skin age has been reduced were reported as prohibited together. The words a brief most wants to borrow from the procedure market are gathered right here.

The workable alternative is to write the use outcome rather than the material name. Copy that leans on a material's topicality has to be rewritten each time you try to avoid a prohibited phrase. Copy written around what changes in which situation only needs its strength adjusted within the range of the test data you hold, so it does not wobble at review.

• Whether the material's origin — human, plant, milk — is settled in one line
• Whether words that would fall under prohibited expressions were screened out of pack and page copy first
• Whether expert-recommendation wording such as 'for hospital use' is being used
• Whether the claim was rewritten as a use outcome rather than an ingredient name

4. Accreditation and clearance wording is not evidence of safety

The advertising point raised at the audit transfers directly to cosmetics. Kim Yun questioned wording citing AATB accreditation, FDA raw material clearance and MFDS approval, noting that AATB accredits tissue banks rather than products, and that neither the FDA nor the MFDS procedure constitutes a verified safety and efficacy approval.

That distinction blurs often on cosmetic product pages. An accreditation held by an ingredient supplier, one held by a manufacturing site, and a review granted to a product each certify something different. The fact that an ingredient is registered with a body speaks to the ingredient's identity, not to the finished product having its efficacy recognised by that body.

The usable rule for planning is simple. Each time a body's name appears in copy, write in brackets what that body approved. If you cannot write whether it was the ingredient, the facility or the product, the phrase is better left out.

The background is also worth noting. As the commissioner acknowledged, the Human Tissue Act carried no advertising provision at all. Cosmetics, by contrast, already have labelling and advertising rules and prohibited-expression guidance. Having rules can look like the more awkward position, but a clear standard also makes the scope of any copy revision calculable in advance.

• Whether every phrase naming a body can state what was approved — ingredient, facility or product
• Whether a supplier's accreditation is being carried over as evidence of finished-product efficacy
• Whether overseas accreditation wording is being used as is in domestic copy
• Whether finished-product test data is held separately as the basis for efficacy wording

5. Assume export and one more line appears

Clearing the Korean standard does not open the export route in this category. According to a summary by the regulatory consultancy REACH24H, the European Union and China prohibit the use of human cells and tissues or human-derived products as cosmetic ingredients. The same material reports that Health Canada published a final notice on the classification of topical products containing human-derived exosomes on 10 April 2026. It is a secondary summary, so each country's own documents have to be checked before entering a market.

The implication for planning is clear. A product premised on a human-derived material starts with a narrower set of sellable markets. Splitting into domestic and export formulas doubles both development cost and inventory, and developing a separate export formula pushes the whole launch back.

So the realistic choice here is to design with a non-human-derived material from the start. If a clearly originated material — plant, microbial, fermentation — can produce a similar use outcome, domestic labelling constraints lighten and export markets stay open. There is no guarantee that a differently originated material delivers the same result, so treat the switch as a development hypothesis and confirm it with finished-product testing.

Watch the schedule too. This category takes longer on ingredient qualification and copy review than on formulation. If export is assumed, start destination-market ingredient rule checks on the same line as formulation, and write down at the brief stage which markets you are prepared to give up.

• Whether the sellable markets are written in the brief when a human-derived material is used
• Whether the added cost and time of splitting domestic and export formulas were calculated
• Whether a clearly originated alternative material was examined for the same use outcome
• Whether destination-market ingredient rule checks sit on the same schedule line as formulation

The first question for the brief

Instead of writing 'that ingredient everyone is talking about', write what the material comes from. Settling in one line whether it is human-derived or plant or microbial in origin decides, in the same sentence, whether it is a usable ingredient, a sayable claim and a shippable market.

The second thing to write is the order. Formulation is not the first cell in this category. Confirming the ingredient's identity and securing the supplier's records is the first cell, then the contract recording retention responsibility, then the format. Reversing the order means the cost of coming back is more than the cost of samples.

The last is the copy. Write down now the words you intend to use in the claim, and mark each as either an ingredient name or a use outcome. If it leans on the ingredient name, every change to the guidance means rewriting all of it. Written as a use outcome, the scope of any rewrite narrows to the range of your test data.